Teleflex Stock: Analyst Estimates & Ratings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2025
0mins
Source: NASDAQ.COM
Teleflex's Financial Performance: Teleflex Incorporated has seen a significant decline in its stock, dropping 22% over the past year, and reported disappointing Q3 results with a modest revenue increase of 2.4%, missing expectations, and a notable decrease in operating income.
Analyst Ratings and Future Outlook: The consensus rating for Teleflex stock is a "Moderate Buy," but recent analyst actions have lowered price targets, indicating cautious sentiment, while the company is expected to report a modest EPS growth in its upcoming fiscal results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TFX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TFX
Wall Street analysts forecast TFX stock price to rise
7 Analyst Rating
1 Buy
5 Hold
1 Sell
Hold
Current: 119.890
Low
122.00
Averages
136.20
High
155.00
Current: 119.890
Low
122.00
Averages
136.20
High
155.00
About TFX
Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of Arrow branded intra-aortic balloon pumps and catheters, GuideLiner, Turnpike and TrapLiner catheters, Pulsar-18 T3 Self-Expanding 4F Stent and Orsiro Mission Drug Eluting Stent.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teleflex Appoints New CEO to Drive Strategic Growth
- New CEO Appointment: Teleflex announced that Jason Weidman will officially take over as CEO on June 8, 2026, succeeding Stuart Randle, who has served as interim CEO since January and will remain on the board to ensure a smooth leadership transition.
- Extensive Leadership Experience: Weidman joins from Medtronic, where he held senior leadership roles, most recently overseeing major cardiovascular businesses and global expansion, which is expected to bring valuable industry experience and strategic insight to Teleflex.
- Board Membership Change: Upon assuming the role, Weidman will also join the board, a change that not only strengthens corporate governance but also provides robust leadership support for future strategic decisions.
- Positive Market Reaction: Following the announcement of the appointment, Teleflex's stock saw an uptick, reflecting investor confidence in the new leadership and optimistic expectations for the company's future growth.
See More
Teleflex Appoints New CEO to Drive Growth
- Leadership Change: Teleflex announced the appointment of Jason Weidman as President and CEO effective June 8, 2026, succeeding Stuart Randle, who has served as Interim CEO since January 2026, marking a significant leadership transition aimed at driving future growth and value creation.
- Extensive Industry Experience: Weidman brings over 25 years of experience in the medical technology sector, having held various senior leadership roles at Medtronic, most recently overseeing the Coronary & Renal Denervation business, where he successfully drove global expansion of multi-billion dollar revenue units, showcasing his deep industry background and capabilities.
- Strategic Focus: Teleflex plans to reshape its capital structure with a $1 billion share buyback and $800 million debt paydown, and Weidman's leadership is expected to enhance the company's strategic focus on core interventional, critical care, and high acuity hospital markets, thereby improving its competitive position.
- Innovation-Driven Future: Weidman expressed that joining Teleflex at this pivotal moment presents a clear opportunity to leverage his medical technology expertise to further advance innovation and market development, committed to improving health and quality of life for people.
See More
Teleflex to Host Q1 2026 Financial Results Conference Call
- Conference Call Schedule: Teleflex will host a conference call on May 7, 2026, at 8:00 a.m. Eastern Time to discuss its Q1 financial results and provide an operational update, aiming to enhance investor understanding of the company's performance.
- Participation Details: Investors can pre-register via a provided link to receive dial-in information, and the call will also be accessible through a live audio webcast on the company's website, ensuring broad participation and transparency.
- Replay Information: An audio replay of the call will be available starting at 11:00 a.m. on May 7, 2026, allowing investors who cannot attend live to access the information through the Teleflex website or designated phone numbers.
- Company Background: Teleflex is a global provider of medical technologies focused on improving health and quality of life, with a diverse portfolio covering anesthesia, emergency medicine, interventional cardiology, and more, showcasing its leadership in the healthcare industry.
See More
Teleflex (TFX) Q4 2024 Earnings Transcript
See More
Teleflex Shares Surge 9.7% on Takeover Speculation
- Stock Surge on Acquisition Rumors: Teleflex (TFX) shares rose 9.7% following reports that CVC Capital Partners and GTCR are considering a takeover, reflecting market optimism about a potential deal.
- PE Firms Collaboration: CVC and GTCR are jointly evaluating the possibility of acquiring Teleflex, although it remains unclear if Teleflex would be receptive to such an approach, and there is no guarantee that a transaction will materialize.
- Activist Investor Pressure: Activist investor Irenic Capital Management sent a letter to Teleflex last month urging the company to explore strategic alternatives, including a potential buyout and board overhaul, highlighting concerns over corporate governance.
- Future Outlook and Financial Guidance: Teleflex projects earnings per share between $6.25 and $6.55 for 2026 and plans a $1 billion share repurchase, demonstrating financial stability and commitment to shareholders amid its ongoing portfolio transformation.
See More
Teleflex Stock Rises 9% in Premarket Trading Following Joint Take-Private Offer from CVC and GTCR
Teleflex Shares Surge: Teleflex shares increased by 9% in pre-market trading following a report of a joint venture with GTC, indicating positive investor sentiment.
Private Bid Speculation: The rise in shares is attributed to speculation surrounding a potential private bid for the company, which has generated interest among investors.
See More
Teleflex Appoints New CEO to Drive Strategic Growth
- New CEO Appointment: Teleflex announced that Jason Weidman will officially take over as CEO on June 8, 2026, succeeding Stuart Randle, who has served as interim CEO since January and will remain on the board to ensure a smooth leadership transition.
- Extensive Leadership Experience: Weidman joins from Medtronic, where he held senior leadership roles, most recently overseeing major cardiovascular businesses and global expansion, which is expected to bring valuable industry experience and strategic insight to Teleflex.
- Board Membership Change: Upon assuming the role, Weidman will also join the board, a change that not only strengthens corporate governance but also provides robust leadership support for future strategic decisions.
- Positive Market Reaction: Following the announcement of the appointment, Teleflex's stock saw an uptick, reflecting investor confidence in the new leadership and optimistic expectations for the company's future growth.
See More
Teleflex Appoints New CEO to Drive Growth
- Leadership Change: Teleflex announced the appointment of Jason Weidman as President and CEO effective June 8, 2026, succeeding Stuart Randle, who has served as Interim CEO since January 2026, marking a significant leadership transition aimed at driving future growth and value creation.
- Extensive Industry Experience: Weidman brings over 25 years of experience in the medical technology sector, having held various senior leadership roles at Medtronic, most recently overseeing the Coronary & Renal Denervation business, where he successfully drove global expansion of multi-billion dollar revenue units, showcasing his deep industry background and capabilities.
- Strategic Focus: Teleflex plans to reshape its capital structure with a $1 billion share buyback and $800 million debt paydown, and Weidman's leadership is expected to enhance the company's strategic focus on core interventional, critical care, and high acuity hospital markets, thereby improving its competitive position.
- Innovation-Driven Future: Weidman expressed that joining Teleflex at this pivotal moment presents a clear opportunity to leverage his medical technology expertise to further advance innovation and market development, committed to improving health and quality of life for people.
See More
Teleflex to Host Q1 2026 Financial Results Conference Call
- Conference Call Schedule: Teleflex will host a conference call on May 7, 2026, at 8:00 a.m. Eastern Time to discuss its Q1 financial results and provide an operational update, aiming to enhance investor understanding of the company's performance.
- Participation Details: Investors can pre-register via a provided link to receive dial-in information, and the call will also be accessible through a live audio webcast on the company's website, ensuring broad participation and transparency.
- Replay Information: An audio replay of the call will be available starting at 11:00 a.m. on May 7, 2026, allowing investors who cannot attend live to access the information through the Teleflex website or designated phone numbers.
- Company Background: Teleflex is a global provider of medical technologies focused on improving health and quality of life, with a diverse portfolio covering anesthesia, emergency medicine, interventional cardiology, and more, showcasing its leadership in the healthcare industry.
See More
Teleflex (TFX) Q4 2024 Earnings Transcript
See More
Teleflex Shares Surge 9.7% on Takeover Speculation
- Stock Surge on Acquisition Rumors: Teleflex (TFX) shares rose 9.7% following reports that CVC Capital Partners and GTCR are considering a takeover, reflecting market optimism about a potential deal.
- PE Firms Collaboration: CVC and GTCR are jointly evaluating the possibility of acquiring Teleflex, although it remains unclear if Teleflex would be receptive to such an approach, and there is no guarantee that a transaction will materialize.
- Activist Investor Pressure: Activist investor Irenic Capital Management sent a letter to Teleflex last month urging the company to explore strategic alternatives, including a potential buyout and board overhaul, highlighting concerns over corporate governance.
- Future Outlook and Financial Guidance: Teleflex projects earnings per share between $6.25 and $6.55 for 2026 and plans a $1 billion share repurchase, demonstrating financial stability and commitment to shareholders amid its ongoing portfolio transformation.
See More
Teleflex Stock Rises 9% in Premarket Trading Following Joint Take-Private Offer from CVC and GTCR
Teleflex Shares Surge: Teleflex shares increased by 9% in pre-market trading following a report of a joint venture with GTC, indicating positive investor sentiment.
Private Bid Speculation: The rise in shares is attributed to speculation surrounding a potential private bid for the company, which has generated interest among investors.
See More
